On the morning of August 25th, Zhang Ying, Vice Chairman of Shanghai Municipal Commission of Economy and Informatization, led a team to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Accutar Biotechnology (Shanghai) Co., Ltd. to investigate and understand the current development of these organizations, coordinate and solve the problems encountered in the development of enterprises, and accelerate the key technological breakthroughs in the field of AI-enabled drug R&D.
At Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Ms. Zhang listened to the important breakthroughs made by the Institute in drug design based on artificial intelligence and big data, and the critical contributions to the construction of basic platform for AI-enabled drug R&D. She hoped that the Institute could continue to deepen research in the field of AI-enabled drug R&D and strengthen the basic innovation capability of artificial intelligence.
At Accutar Biotechnology (Shanghai) Co., Ltd., Ms. Zhang had an in-depth discussion with the enterprise, listened about its development, visited the drug R&D laboratory and fully communicated with the enterprise on AI-enabled drug R&D in Shanghai. She expressed her appreciation for Accutar Biotech's achievements in AI-enabled drug design, and hoped that the enterprise would continue to strengthen technological R&D, expand development scale and business scope, and occupy a place in the global AI-assisted drug R&D competition.
Responsible comrades of Artificial Intelligence Development Department of Shanghai Municipal Commission of Economy and Informatization participated in the investigation.
